副甲状腺ホルモンと25-ヒドロキシビタミンD3:腎臓のリン酸輸送に相乗効果と相反効果がある
まとめ
副甲状腺ホルモン (PTH) と25-ヒドロキシコレカルシフェロール (25-HCC) は,ネズミのリン酸分泌を調節するために一緒に作用します. 高用量のPTHだけでフォスファチューリアを引き起こしますが,低用量では25-HCCが必要です.
科学分野:
- エンドクリノロジー エンドクリノロジー
- 腎臓生理学 腎臓生理学
- ミネラルメタボリズム
背景:
- 副甲状腺ホルモン (PTH) とビタミンDは,カルシウムとリン酸ホメオスタシスの重要な調節因子です.
- リン酸分泌におけるPTHとビタミンDの代謝産物の相互作用は複雑である.
- これらの相互作用を理解することは,鉱物不均衡の管理に極めて重要です.
研究 の 目的:
- 副甲状腺ホルモン (PTH) と25-hydroxycholecalciferol (25-HCC) の異なる用量の腎臓のリン酸分泌に対する影響を調査する.
- リン酸調節におけるPTHと25-HCCの相乗的または独立した役割を決定する.
- 制御された動物モデルで用量依存の反応を確立するために.
主な方法:
- 固有のホルモン影響を排除するために,チロパチロイド切除され,ビタミンDが不足したラットを使用しました.
- 25-HCCとPTHの分級投与量を,個別に,または組み合わせて,連続注入で投与しました.
- ホルモン治療への反応として尿中のリン酸分泌をモニターする.
主要な成果:
- 低用量25-HCC (1単位/時間) は,低用量PTH (0.2単位/時間) と組み合わせた場合にのみ,アンチフォスファチューリアを誘発した.
- 中量のPTH (2.0単位/時間) は,フォスファチューリアを誘発するために25-HCC (1単位/時間) の併用が必要でした.
- 高用量PTH (5単位/時間) は,25-HCCなしでもフォスファチューリアを引き起こし,用量依存的効果を示した.
結論:
- PTHによるリン酸分泌の調節は,PTHのサブ薬理学的レベルでの25-HCCの存在と用量によって著しく影響を受けます.
- PTHと25-HCCの間で,低濃度でのリン酸バランスの維持のために,相乗効果の相互作用が存在します.
- PTHの薬理学的用量は,フォスファートの排泄を促進するために25-HCCの要件を覆すことができます.
さらに関連する動画
関連する概念動画
Hormones and Bone Tissue
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...


